Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Epic Bio

Main focus: CRISPR-based epigenetic engineering

Company stage: Pre-clinical

Diseases (gene editing): Facioscapulohumeral Muscular Dystrophy (FSHD), Heterozygous Familial Hypercholesterolemia (HeFH), Alpha-1 Antitrypsin Deficiency (A1AD), Retinitis Pigmentosa 4 (RP4), Retinitis Pigmentosa 11 (RP11)

Genome editing tool: CRISPR activation/CRISPR inhibition

Funding stage: Private

Location: South San Francisco, CA, USA

Website: https://epic-bio.com/

Pipeline: https://epic-bio.com/pipeline/

Epic Bio is a start-up company focused on epigenetic engineering using the CRISPR-Cas system. The company holds an exclusive license to a Cas enzyme called CasMINI, which is the smallest and most deliverable dCas protein to date, which can then be engineered with a modulating protein to attain activating- or inhibitory effects.

Tags

HashtagEpic Bio

Company: Epic Bio
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine